Natera (NTRA) said Wednesday that the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.
The company said the test screens for 21 genes that are linked to serious early-onset conditions.
Natera said the trial has shown strong early performance results and confirmed outcomes against genetic testing benchmarks, including accurate detection in rare homozygous cases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments